Wednesday, June 19, 2013 Last update: 3:56 AM
Company Tech News as it Breaks
Telik, Inc.
News articles for Telik, Inc.:
Friday, May 10, 2013
- Telik Announces First Quarter 2013 Financial ResultsPALO ALTO, Calif., May 10, 2013 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss ... read more
Friday, March 15, 2013
- Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial GuidancePALO ALTO, Calif., March 15, 2013 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $1.8 million, or $0.66 per share, for the three months ended December 31, 2012, compared with a net loss of $2.5 million, or $1.38 per share, for the comparable period in 2011. ... read more
Tuesday, January 22, 2013
- Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic SyndromePALO ALTO, Calif., Jan. 22, 2013 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced the completion of an End of Phase 2 meeting with the US Food and Drug Administration (FDA). Preliminary agreement was reached regarding the design of a Phase 3 placebo-controlled randomized registration trial of ... read more
Friday, January 11, 2013
- Telik Announces Orphan Designation Of Telintra® For Treatment Of Myelodysplastic SyndromePALO ALTO, Calif., Jan. 11, 2013 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) was notified today that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS). Orphan designation grants ... read more